OncoGenex Pharmaceuticals Inc Overview

State:Washington
Country:United States
Industry:Biotechnology and Drugs
Description:
OncoGenex Pharmaceuticals, Inc. (OncoGenex) is a biopharmaceutical company engaged in the development and commercialization of cancer therapies. As of December 31, 2009, the Company had three clinical-stage product candidates (OGX-011, OGX-427 and SN2310) and two pre-clinical-stage product candidates (CSP-9222 and OGX-225). OncoGenex’s product candidates, OGX-011, OGX-427 and OGX-225, focus on mechanisms of treatment resistance in cancer patients and are designed to address treatment resistance by blocking the production of specific proteins, which promote survival of tumor cells and are over-produced in response to a variety of cancer treatments. Product candidate SN2310 is a camptothecin for the treatment of cancer. Product candidate CSP-9222 is the lead compound from a family of compounds, which... (More)

Get Trial Access to OneSource

Company profiles, executive contacts, industry research, and news for sales, marketing and research professionals.

Disclaimer: While the OneSource Subscription Service maintains the freshest, most accurate data possible, this free site is refreshed on a periodic basis and may occasionally contain information that is not current. If you would like to alert us to a change, please email us, and we will take steps to make sure your update is included as soon as possible

OncoGenex Pharmaceuticals Inc Overview

Get Trial Access to OneSource

Business Information

Executive Profiles

Company Lists